{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:37:11Z","timestamp":1780087031358,"version":"3.54.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00296-020-04515-6","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T11:03:09Z","timestamp":1579518189000},"page":"679-694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Is biological therapy in systemic sclerosis the answer?"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-7396","authenticated-orcid":false,"given":"Durga Prasanna","family":"Misra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-311X","authenticated-orcid":false,"given":"Sakir","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4508-1233","authenticated-orcid":false,"given":"Vikas","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"key":"4515_CR1","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s00296-017-3826-y","volume":"38","author":"DR Poudel","year":"2018","unstructured":"Poudel DR, Jayakumar D, Danve A, Sehra ST, Derk CT (2018) Determinants of mortality in systemic sclerosis: a focused review. Rheumatol Int 38:1847\u20131858. https:\/\/doi.org\/10.1007\/s00296-017-3826-y","journal-title":"Rheumatol Int"},{"key":"4515_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00296-017-3916-x","volume":"38","author":"D S\u00e1nchez-Cano","year":"2018","unstructured":"S\u00e1nchez-Cano D, Ortego-Centeno N, Callejas JL et al (2018) Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Rheumatol Int 38:363\u2013374. https:\/\/doi.org\/10.1007\/s00296-017-3916-x","journal-title":"Rheumatol Int"},{"key":"4515_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","volume":"6","author":"D Pattanaik","year":"2015","unstructured":"Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE (2015) Pathogenesis of systemic sclerosis. Front Immunol 6:272\u2013272. https:\/\/doi.org\/10.3389\/fimmu.2015.00272","journal-title":"Front Immunol"},{"key":"4515_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5301\/jsrd.5000249","volume":"2","author":"J Varga","year":"2017","unstructured":"Varga J, Trojanowska M, Kuwana M (2017) Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord 2:137\u2013152. https:\/\/doi.org\/10.5301\/jsrd.5000249","journal-title":"J Scleroderma Relat Disord"},{"key":"4515_CR5","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00296-019-04317-5","volume":"39","author":"S Ahmed","year":"2019","unstructured":"Ahmed S, Misra DP, Agarwal V (2019) Interleukin-17 pathways in systemic sclerosis-associated fibrosis. Rheumatol Int 39:1135\u20131143. https:\/\/doi.org\/10.1007\/s00296-019-04317-5","journal-title":"Rheumatol Int"},{"key":"4515_CR6","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","volume":"8","author":"D Chakraborty","year":"2017","unstructured":"Chakraborty D, Sumova B, Mallano T et al (2017) Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun 8:1130. https:\/\/doi.org\/10.1038\/s41467-017-01236-6","journal-title":"Nat Commun"},{"key":"4515_CR7","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1093\/rheumatology\/kex347","volume":"57","author":"M Pedroza","year":"2018","unstructured":"Pedroza M, To S, Assassi S, Wu M, Tweardy D, Agarwal SK (2018) Role of STAT3 in skin fibrosis and transforming growth factor beta signalling. Rheumatology (Oxford) 57:1838\u20131850. https:\/\/doi.org\/10.1093\/rheumatology\/kex347","journal-title":"Rheumatology (Oxford)"},{"key":"4515_CR8","doi-asserted-by":"publisher","first-page":"e0172191","DOI":"10.1371\/journal.pone.0172191","volume":"12","author":"JF Yan","year":"2017","unstructured":"Yan JF, Huang WJ, Zhao JF et al (2017) The platelet-derived growth factor receptor\/STAT3 signaling pathway regulates the phenotypic transition of corpus cavernosum smooth muscle in rats. PLoS ONE 12:e0172191. https:\/\/doi.org\/10.1371\/journal.pone.0172191","journal-title":"PLoS ONE"},{"key":"4515_CR9","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/1756-185x.13386","volume":"21","author":"S Chaturvedi","year":"2018","unstructured":"Chaturvedi S, Misra DP, Prasad N et al (2018) 5-HT2 and 5-HT2B antagonists attenuate pro-fibrotic phenotype in human adult dermal fibroblasts by blocking TGF-beta1 induced non-canonical signaling pathways including STAT3: implications for fibrotic diseases like scleroderma. Int J Rheum Dis 21:2128\u20132138. https:\/\/doi.org\/10.1111\/1756-185x.13386","journal-title":"Int J Rheum Dis"},{"key":"4515_CR10","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"4515_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","volume":"180","author":"S Kitaba","year":"2012","unstructured":"Kitaba S, Murota H, Terao M et al (2012) Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 180:165\u2013176. https:\/\/doi.org\/10.1016\/j.ajpath.2011.09.013","journal-title":"Am J Pathol"},{"key":"4515_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/1346-8138.13827","volume":"44","author":"T Taniguchi","year":"2017","unstructured":"Taniguchi T, Asano Y, Fukasawa T, Yoshizaki A, Sato S (2017) Critical contribution of the interleukin-6\/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis. J Dermatol 44:967\u2013971. https:\/\/doi.org\/10.1111\/1346-8138.13827","journal-title":"J Dermatol"},{"key":"4515_CR13","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/j.bbmt.2011.07.001","volume":"17","author":"WR Drobyski","year":"2011","unstructured":"Drobyski WR, Pasquini M, Kovatovic K et al (2011) Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant 17:1862\u20131868. https:\/\/doi.org\/10.1016\/j.bbmt.2011.07.001","journal-title":"Biol Blood Marrow Transplant"},{"key":"4515_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5301\/jsrd.5000259","volume":"2","author":"I Foeldvari","year":"2017","unstructured":"Foeldvari I, Anton J, Friswell M et al (2017) Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma patients. J Scleroderma Relat Disord 2:203\u2013207. https:\/\/doi.org\/10.5301\/jsrd.5000259","journal-title":"J Scleroderma Relat Disord"},{"key":"4515_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/rheumatology\/kex382","volume":"57","author":"H Lythgoe","year":"2018","unstructured":"Lythgoe H, Baildam E, Beresford MW, Cleary G, McCann LJ, Pain CE (2018) Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. Rheumatology (Oxford) 57:398\u2013401. https:\/\/doi.org\/10.1093\/rheumatology\/kex382","journal-title":"Rheumatology (Oxford)"},{"key":"4515_CR16","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A et al (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387:2630\u20132640. https:\/\/doi.org\/10.1016\/S0140-6736(16)00232-4","journal-title":"Lancet"},{"key":"4515_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"D Khanna","year":"2018","unstructured":"Khanna D, Denton CP, Lin CJF et al (2018) Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 77:212\u2013220. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211682","journal-title":"Ann Rheum Dis"},{"key":"4515_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/rheumatology\/kex396","volume":"57","author":"MB Arnold","year":"2018","unstructured":"Arnold MB, Khanna D, Denton CP et al (2018) Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 57:152\u2013157. https:\/\/doi.org\/10.1093\/rheumatology\/kex396","journal-title":"Rheumatology (Oxford)"},{"key":"4515_CR19","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","volume":"77","author":"CP Denton","year":"2018","unstructured":"Denton CP, Ong VH, Xu S et al (2018) Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: Insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis 77:1362\u20131371. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213031","journal-title":"Ann Rheum Dis"},{"key":"4515_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1080\/14397595.2018.1452178","volume":"29","author":"Y Shima","year":"2019","unstructured":"Shima Y, Kawaguchi Y, Kuwana M (2019) Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy. Mod Rheumatol 29:134\u2013139. https:\/\/doi.org\/10.1080\/14397595.2018.1452178","journal-title":"Mod Rheumatol"},{"key":"4515_CR21","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","volume":"72","author":"M Elhai","year":"2013","unstructured":"Elhai M, Meunier M, Matucci-Cerinic M et al (2013) Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 72:1217\u20131220. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202657","journal-title":"Ann Rheum Dis"},{"key":"4515_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/03009742.2017.1297482","volume":"47","author":"M Kono","year":"2018","unstructured":"Kono M, Yasuda S, Kono M, Atsumi T (2018) Tocilizumab reduced production of systemic sclerosis-related autoantibodies and anti-cyclic citrullinated protein antibodies in two patients with overlapping systemic sclerosis and rheumatoid arthritis. Scand J Rheumatol 47:248\u2013250. https:\/\/doi.org\/10.1080\/03009742.2017.1297482","journal-title":"Scand J Rheumatol"},{"key":"4515_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41927-019-0063-x","volume":"3","author":"H Wakabayashi","year":"2019","unstructured":"Wakabayashi H, Kino H, Kondo M, Yamanaka K, Hasegawa M, Sudo A (2019) Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature. BMC Rheumatol 3:15. https:\/\/doi.org\/10.1186\/s41927-019-0063-x","journal-title":"BMC Rheumatol"},{"key":"4515_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/rheumatology\/keu435","volume":"54","author":"MF Das Neves","year":"2015","unstructured":"Das Neves MF, Oliveira S, Amaral MC, Alves JD (2015) Treatment of systemic sclerosis with tocilizumab. Rheumatology (Oxford) 54:371\u2013372. https:\/\/doi.org\/10.1093\/rheumatology\/keu435","journal-title":"Rheumatology (Oxford)"},{"key":"4515_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.berh.2019.01.011","volume":"32","author":"G Zacay","year":"2018","unstructured":"Zacay G, Levy Y (2018) Outcomes of patients with systemic sclerosis treated with tocilizumab: case series and review of the literature. Best Pract Res Clin Rheumatol 32:563\u2013571. https:\/\/doi.org\/10.1016\/j.berh.2019.01.011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"4515_CR26","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina A, Walker KM, Pope JE (2018) Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 70:1820\u20131828. https:\/\/doi.org\/10.1002\/art.40560","journal-title":"Arthritis Rheumatol"},{"key":"4515_CR27","unstructured":"Khanna D, Lin CJF, Kuwana M, et al. (2018) Efficacy and safety of tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial [abstract]. Arthritis Rheumatol 70 (suppl 10)."},{"key":"4515_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0022-510X(02)00309-X","volume":"205","author":"KY Murata","year":"2002","unstructured":"Murata KY, Sugie K, Takamure M, Ueno S (2002) Expression of the costimulatory molecule BB-1 and its receptors in patients with scleroderma-polymyositis overlap syndrome. J Neurol Sci 205:65\u201370. https:\/\/doi.org\/10.1016\/S0022-510X(02)00309-X","journal-title":"J Neurol Sci"},{"key":"4515_CR29","first-page":"823","volume":"20","author":"F Takeuchi","year":"2002","unstructured":"Takeuchi F, Kawasugi K, Nabeta H, Mori M, Tanimoto K (2002) Association of CTLA-4 with systemic sclerosis in Japanese patients. Clin Exp Rheumatol 20:823\u2013828","journal-title":"Clin Exp Rheumatol"},{"key":"4515_CR30","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1136\/annrheumdis-2015-208213","volume":"75","author":"M Ponsoye","year":"2016","unstructured":"Ponsoye M, Frantz C, Ruzehaji N et al (2016) Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. Ann Rheum Dis 75:2142\u20132149. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208213","journal-title":"Ann Rheum Dis"},{"key":"4515_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13075-018-1652-6","volume":"20","author":"M Cutolo","year":"2018","unstructured":"Cutolo M, Soldano S, Montagna P et al (2018) Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay. Arthritis Res Ther 20:157.\u00a0https:\/\/doi.org\/10.1186\/s13075-018-1652-6","journal-title":"Arthritis Res Ther"},{"key":"4515_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/art.41055","volume":"72","author":"D Khanna","year":"2020","unstructured":"Khanna D, Spino C, Johnson S et al (2020) Abatacept in early diffuse cutaneous systemic sclerosis results of a phase 2 investigator-initiated, multicenter, double-blind randomized placebo-controlled trial. Arthritis Rheumatol 72:125\u2013136. https:\/\/doi.org\/10.1002\/art.41055","journal-title":"Arthritis Rheumatol"},{"key":"4515_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13075-015-0669-3","volume":"17","author":"EF Chakravarty","year":"2015","unstructured":"Chakravarty EF, Martyanov V, Fiorentino D et al (2015) Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Res Ther 17:159. https:\/\/doi.org\/10.1186\/s13075-015-0669-3","journal-title":"Arthritis Res Ther"},{"key":"4515_CR34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2340\/00015555-2878","volume":"98","author":"S Wehner Fage","year":"2018","unstructured":"Wehner Fage S, Arvesen KB, Olesen AB (2018) Abatacept improves skin-score and reduces lesions in patients with localized scleroderma: a case series. Acta Derm Venereol 98:465\u2013466. https:\/\/doi.org\/10.2340\/00015555-2878","journal-title":"Acta Derm Venereol"},{"key":"4515_CR35","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2340\/00015555-1136","volume":"91","author":"B Stausb\u00f8l-Gr\u00f8n","year":"2011","unstructured":"Stausb\u00f8l-Gr\u00f8n B, Olesen AB, Deleuran B, Deleuran MS (2011) Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases. Acta Derm Venereol 91:686\u2013688. https:\/\/doi.org\/10.2340\/00015555-1136","journal-title":"Acta Derm Venereol"},{"key":"4515_CR36","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3109\/03009742.2013.812238","volume":"43","author":"FV De Paoli","year":"2014","unstructured":"De Paoli FV, Nielsen BD, Rasmussen F, Deleuran B, S\u00f8ndergaard K (2014) Abatacept induces clinical improvement in patients with severe systemic sclerosis. Scand J Rheumatol 43:342\u2013345. https:\/\/doi.org\/10.3109\/03009742.2013.812238","journal-title":"Scand J Rheumatol"},{"key":"4515_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/rheumatology\/kem344","volume":"47","author":"SS Koca","year":"2008","unstructured":"Koca SS, Isik A, Ozercan IH, Ustundag B, Evren B, Metin K (2008) Effectiveness of etanercept in bleomycin-induced experimental scleroderma. Rheumatology (Oxford) 47:172\u2013175. https:\/\/doi.org\/10.1093\/rheumatology\/kem344","journal-title":"Rheumatology (Oxford)"},{"key":"4515_CR38","doi-asserted-by":"publisher","first-page":"e6737","DOI":"10.1097\/MD.0000000000006737","volume":"96","author":"T Li","year":"2017","unstructured":"Li T, Liu Y, Xu H (2017) Successful treatment of infliximab in a patient with scleroderma: a case report. Medicine (Baltimore). 96:e6737.\u00a0https:\/\/doi.org\/10.1097\/MD.0000000000006737","journal-title":"Medicine (Baltimore)"},{"key":"4515_CR39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/18743129014090100030","volume":"9","author":"ID Ferguson","year":"2015","unstructured":"Ferguson ID, Weiser P, Torok KS (2015) A case report of successful treatment of recalcitrant childhood localized scleroderma with infliximab and leflunomide. Open Rheumatol 9:30\u201335. https:\/\/doi.org\/10.2174\/18743129014090100030","journal-title":"Open Rheumatol"},{"key":"4515_CR40","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000090248","volume":"75","author":"E Bargagli","year":"2008","unstructured":"Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P (2008) Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 75:346\u2013349. https:\/\/doi.org\/10.1159\/000090248","journal-title":"Respiration"},{"key":"4515_CR41","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/archdermatol.2010.120","volume":"146","author":"M Diab","year":"2010","unstructured":"Diab M, Coloe JR, Magro C, Bechtel MA (2010) Treatment of recalcitrant generalized morphea with infliximab. Arch Dermatol 146:601\u2013604. https:\/\/doi.org\/10.1001\/archdermatol.2010.120","journal-title":"Arch Dermatol"},{"key":"4515_CR42","first-page":"23","volume":"25","author":"KM Antoniou","year":"2007","unstructured":"Antoniou KM, Mamoulaki M, Malagari K et al (2007) Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 25:23\u201328","journal-title":"Clin Exp Rheumatol"},{"key":"4515_CR43","first-page":"1636","volume":"34","author":"GK Lam","year":"2007","unstructured":"Lam GK, Hummers LK, Woods A, Wigley FM (2007) Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 34:1636\u20131637","journal-title":"J Rheumatol"},{"key":"4515_CR44","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/rheumatology\/ket365","volume":"53","author":"S Tosounidou","year":"2014","unstructured":"Tosounidou S, Macdonald H, Situnayake D (2014) Successful treatment of calcinosis with infliximab in a patient with systemic sclerosis\/myositis overlap syndrome. Rheumatology (Oxford) 53:960\u2013961. https:\/\/doi.org\/10.1093\/rheumatology\/ket365","journal-title":"Rheumatology (Oxford)"},{"key":"4515_CR45","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1136\/ard.2008.096123","volume":"68","author":"CP Denton","year":"2009","unstructured":"Denton CP, Engelhart M, Tvede N et al (2009) An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 68:1433\u20131439. https:\/\/doi.org\/10.1136\/ard.2008.096123","journal-title":"Ann Rheum Dis"},{"key":"4515_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/01.rhu.0000191162.66288.27","volume":"11","author":"P Ranganathan","year":"2005","unstructured":"Ranganathan P (2005) Infliximab-induced scleredema in a patient with rheumatoid arthritis. J Clin Rheumatol 11:319\u2013322. https:\/\/doi.org\/10.1097\/01.rhu.0000191162.66288.27","journal-title":"J Clin Rheumatol"},{"key":"4515_CR47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1684\/ejd.2013.1929","volume":"23","author":"MS Chimenti","year":"2013","unstructured":"Chimenti MS, Teoli M, Di Stefani A, Giunta A, Esposito M, Perricone R (2013) Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis. Eur J Dermatol 23:273\u2013274. https:\/\/doi.org\/10.1684\/ejd.2013.1929","journal-title":"Eur J Dermatol"},{"key":"4515_CR48","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10165-011-0550-4","volume":"22","author":"J Ram\u00edrez","year":"2012","unstructured":"Ram\u00edrez J, Hern\u00e1ndez MV, Galve J, Canete JD, Sanmart\u00ed R (2012) Morphea associated with the use of adalimumab: a case report and review of the literature. Mod Rheumatol 22:602\u2013604. https:\/\/doi.org\/10.1007\/s10165-011-0550-4","journal-title":"Mod Rheumatol"},{"key":"4515_CR49","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1136\/ard.2005.044453","volume":"65","author":"Y Allanore","year":"2006","unstructured":"Allanore Y, Devos-Fran\u00e7ois G, Caramella C, Boumier P, Jounieaux V, Kahan A (2006) Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 65:834\u2013835. https:\/\/doi.org\/10.1136\/ard.2005.044453","journal-title":"Ann Rheum Dis"},{"key":"4515_CR50","first-page":"S40","volume":"29","author":"JHW Distler","year":"2011","unstructured":"Distler JHW, Jordan S, Air\u00f2 P et al (2011) Is there a role for TNF-\u03b1 antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol 29:S40\u2013S45","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 106","key":"4515_CR51","first-page":"208","volume":"35","author":"A Ichihara","year":"2017","unstructured":"Ichihara A, Jinnin M, Ihn H (2017) Treatment of psoriasis with ustekinumab improved skin tightening in systemic sclerosis. Clin Exp Rheumatol 35(Suppl 106):208\u2013210","journal-title":"Clin Exp Rheumatol"},{"key":"4515_CR52","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jdcr.2019.05.008","volume":"5","author":"AB Steuer","year":"2019","unstructured":"Steuer AB, Peterson E, Lo Sicco K, Franks AG Jr (2019) Morphea in a patient undergoing treatment with ustekinumab. JAAD Case Rep 5:590\u2013592. https:\/\/doi.org\/10.1016\/j.jdcr.2019.05.008","journal-title":"JAAD Case Rep"},{"key":"4515_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.imlet.2017.10.011","volume":"195","author":"M Ciechomska","year":"2018","unstructured":"Ciechomska M, Skalska U (2018) Targeting interferons as a strategy for systemic sclerosis treatment. Immunol Lett 195:45\u201354. https:\/\/doi.org\/10.1016\/j.imlet.2017.10.011","journal-title":"Immunol Lett"},{"key":"4515_CR54","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1186\/ar4492","volume":"16","author":"A Goldberg","year":"2014","unstructured":"Goldberg A, Geppert T, Schiopu E et al (2014) Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther 16:R57. https:\/\/doi.org\/10.1186\/ar4492","journal-title":"Arthritis Res Ther"},{"key":"4515_CR55","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1038\/jid.2015.188","volume":"135","author":"X Guo","year":"2015","unstructured":"Guo X, Higgs BW, Bay-Jensen AC et al (2015) Suppression of T cell activation and collagen accumulation by an anti-IFNAR1 mAb, anifrolumab, in adult patients with systemic sclerosis. J Invest Dermatol 135:2402\u20132409. https:\/\/doi.org\/10.1038\/jid.2015.188","journal-title":"J Invest Dermatol"},{"key":"4515_CR56","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.autrev.2011.04.013","volume":"10","author":"S Bosello","year":"2011","unstructured":"Bosello S, De Luca G, Tolusso B et al (2011) B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 10:624\u2013630. https:\/\/doi.org\/10.1016\/j.autrev.2011.04.013","journal-title":"Autoimmun Rev"},{"key":"4515_CR57","doi-asserted-by":"publisher","first-page":"12319","DOI":"10.1073\/pnas.1635114100","volume":"100","author":"ML Whitfield","year":"2003","unstructured":"Whitfield ML, Finlay DR, Murray JI et al (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100:12319\u201312324. https:\/\/doi.org\/10.1073\/pnas.1635114100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4515_CR58","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/01.rhu.0000129090.86550.1e","volume":"10","author":"FA Wollheim","year":"2004","unstructured":"Wollheim FA (2004) Is rituximab a potential new therapy in systemic sclerosis? new evidence indicates the presence of CD20-positive B-lymphocytes in scleroderma skin. J Clin Rheumatol 10:155. https:\/\/doi.org\/10.1097\/01.rhu.0000129090.86550.1e","journal-title":"J Clin Rheumatol"},{"key":"4515_CR59","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1002\/art.22847","volume":"56","author":"R Lafyatis","year":"2007","unstructured":"Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E (2007) B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 56:3167\u20133168. https:\/\/doi.org\/10.1002\/art.22847","journal-title":"Arthritis Rheum"},{"key":"4515_CR60","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1096\/fj.05-4870fje","volume":"20","author":"S Fineschi","year":"2006","unstructured":"Fineschi S, Reith W, Guerne PA, Dayer JM, Chizzolini C (2006) Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts. FASEB J 20:562\u2013564. https:\/\/doi.org\/10.1096\/fj.05-4870fje","journal-title":"FASEB J"},{"key":"4515_CR61","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/art.24249","volume":"60","author":"R Lafyatis","year":"2009","unstructured":"Lafyatis R, Kissin E, York M et al (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578\u2013583. https:\/\/doi.org\/10.1002\/art.24249","journal-title":"Arthritis Rheum"},{"key":"4515_CR62","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/ard.2008.095463","volume":"69","author":"V Smith","year":"2010","unstructured":"Smith V, Van Praet JT, Vandooren B et al (2010) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69:193\u2013197. https:\/\/doi.org\/10.1136\/ard.2008.095463","journal-title":"Ann Rheum Dis"},{"key":"4515_CR63","doi-asserted-by":"publisher","first-page":"R54","DOI":"10.1186\/ar2965","volume":"12","author":"S Bosello","year":"2010","unstructured":"Bosello S, De Santis M, Lama G et al (2010) B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 12:R54.\u00a0https:\/\/doi.org\/10.1186\/ar2965","journal-title":"Arthritis Res Ther"},{"key":"4515_CR64","first-page":"S17","volume":"30","author":"D Daoussis","year":"2012","unstructured":"Daoussis D, Liossis SNC, Tsamandas AC et al (2012) Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 30:S17\u2013S22","journal-title":"Clin Exp Rheumatol"},{"key":"4515_CR65","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3899\/jrheum.120778","volume":"40","author":"V Smith","year":"2013","unstructured":"Smith V, Piette Y, Van Praet JT et al (2013) Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 40:52\u201357. https:\/\/doi.org\/10.3899\/jrheum.120778","journal-title":"J Rheumatol"},{"key":"4515_CR66","doi-asserted-by":"publisher","first-page":"514","DOI":"10.14412\/1995-4484-2013-1542","volume":"51","author":"LP Ananieva","year":"2013","unstructured":"Ananieva LP, Desinova OV, Koneva OA et al (2013) Rituximab treatment for interstitial lung injury in scleroderma systematica. Nau\u010dno-Prakti\u010deska\u00e2 Revmatologi\u00e2 51:514\u2013523","journal-title":"Nau\u010dno-Prakti\u010deska\u00e2 Revmatologi\u00e2"},{"key":"4515_CR67","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/03009742.2013.869617","volume":"43","author":"FC Moazedi-Fuerst","year":"2014","unstructured":"Moazedi-Fuerst FC, Kielhauser SM, Brickmann K et al (2014) Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen. Scand J Rheumatol 43:257\u2013258. https:\/\/doi.org\/10.3109\/03009742.2013.869617","journal-title":"Scand J Rheumatol"},{"key":"4515_CR68","doi-asserted-by":"publisher","first-page":"495","DOI":"10.14412\/1995-4484-2014-495-506","volume":"52","author":"LP Ananieva","year":"2014","unstructured":"Ananieva LP, Soloviyov SK, Beketova TV et al (2014) Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Nau\u010dno-Prakti\u010deska\u00e2 Revmatologi\u00e2 52:495\u2013506","journal-title":"Nau\u010dno-Prakti\u010deska\u00e2 Revmatologi\u00e2"},{"key":"4515_CR69","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.rbre.2016.06.003","volume":"56","author":"VS Vilela","year":"2016","unstructured":"Vilela VS, Maretti GB, Gama LMdS, Costa CHd, Rufino RL, Levy RA (2016) Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center. Rev Bras Reumatol Engl Ed 56:458\u2013463. https:\/\/doi.org\/10.1016\/j.rbre.2016.06.003","journal-title":"Rev Bras Reumatol Engl Ed"},{"key":"4515_CR70","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/RHU.0000000000000584","volume":"23","author":"A Sari","year":"2017","unstructured":"Sari A, Guven D, Armagan B et al (2017) Rituximab experience in patients with long-standing systemic sclerosis-associated interstitial lung disease: a series of 14 patients. J Clin Rheumatol 23:411\u2013415. https:\/\/doi.org\/10.1097\/RHU.0000000000000584","journal-title":"J Clin Rheumatol"},{"key":"4515_CR71","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4103\/atm.ATM_30_17","volume":"12","author":"AG Mohammed","year":"2017","unstructured":"Mohammed AG, Alshihre A, Al-Homood I (2017) Rituximab treatment in patients with systemic sclerosis and interstitial lung disease. Ann Thorac Med 12:294\u2013297. https:\/\/doi.org\/10.4103\/atm.ATM_30_17","journal-title":"Ann Thorac Med"},{"key":"4515_CR72","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/17843286.2017.1372244","volume":"73","author":"K Melsens","year":"2018","unstructured":"Melsens K, Vandecasteele E, Deschepper E et al (2018) Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clin Belg 73:119\u2013125. https:\/\/doi.org\/10.1080\/17843286.2017.1372244","journal-title":"Acta Clin Belg"},{"key":"4515_CR73","first-page":"591","volume":"56","author":"OA Koneva","year":"2018","unstructured":"Koneva OA, Desinova OV, Ananyeva LP, Kovaleva NV (2018) The importance of high-resolution computed tomography in evaluating the efficacy of rituximab in patients with interstitial lung disease in systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya 56:591\u2013599","journal-title":"Nauchno-Prakticheskaya Revmatologiya"},{"key":"4515_CR74","first-page":"S142","volume":"36","author":"P Fraticelli","year":"2018","unstructured":"Fraticelli P, Fischetti C, Salaffi F et al (2018) Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. a single-centre case series study. Clin Exp Rheumatol 36:S142\u2013S145","journal-title":"Clin Exp Rheumatol"},{"key":"4515_CR75","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1016\/j.jaad.2007.06.010","volume":"58","author":"M Fabri","year":"2008","unstructured":"Fabri M, Hunzelmann N, Krieg T, Rubbert A (2008) Discordant response to rituximab in a systemic sclerosis patient with associated myositis. J Am Acad Dermatol 58:S127\u2013S128. https:\/\/doi.org\/10.1016\/j.jaad.2007.06.010","journal-title":"J Am Acad Dermatol"},{"key":"4515_CR76","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/rheumatology\/kem357","volume":"47","author":"D McGonagle","year":"2008","unstructured":"McGonagle D, Tan AL, Madden J et al (2008) Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 47:552\u2013553. https:\/\/doi.org\/10.1093\/rheumatology\/kem357","journal-title":"Rheumatology (Oxford)"},{"key":"4515_CR77","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.semarthrit.2009.09.003","volume":"40","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis SNC, Tsamandas AC et al (2010) Is there a role for B-cell depletion as therapy for scleroderma? a case report and review of the literature. Semin Arthritis Rheum 40:127\u2013136. https:\/\/doi.org\/10.1016\/j.semarthrit.2009.09.003","journal-title":"Semin Arthritis Rheum"},{"key":"4515_CR78","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1753465811407786","volume":"5","author":"M Haroon","year":"2011","unstructured":"Haroon M, McLaughlin P, Henry M, Harney S (2011) Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 5:299\u2013304. https:\/\/doi.org\/10.1177\/1753465811407786","journal-title":"Ther Adv Respir Dis"},{"key":"4515_CR79","first-page":"131","volume":"11","author":"EI Alexeeva","year":"2012","unstructured":"Alexeeva EI, Valieva SI, Bzarova TM et al (2012) Experience of rituximab treatment in a patient with juvenile scleroderma. Nauchno-Prakticheskaya Revmatologiya 11:131\u2013137","journal-title":"Nauchno-Prakticheskaya Revmatologiya"},{"key":"4515_CR80","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.semarthrit.2011.11.007","volume":"41","author":"D Daoussis","year":"2012","unstructured":"Daoussis D, Antonopoulos I, Liossis SNC, Yiannopoulos G, Andonopoulos AP (2012) Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 41:822\u2013829. https:\/\/doi.org\/10.1016\/j.semarthrit.2011.11.007","journal-title":"Semin Arthritis Rheum"},{"key":"4515_CR81","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10067-012-2124-z","volume":"32","author":"DR De Paula","year":"2013","unstructured":"De Paula DR, Klem FB, Lorencetti PG, Muller C, Azevedo VF (2013) Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol 32:281\u2013283. https:\/\/doi.org\/10.1007\/s10067-012-2124-z","journal-title":"Clin Rheumatol"},{"key":"4515_CR82","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/1346-8138.12461","volume":"41","author":"H Sumida","year":"2014","unstructured":"Sumida H, Asano Y, Tamaki Z et al (2014) Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. J Dermatol 41:418\u2013420. https:\/\/doi.org\/10.1111\/1346-8138.12461","journal-title":"J Dermatol"},{"key":"4515_CR83","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5114\/reum.2016.58760","volume":"54","author":"Q Akram","year":"2016","unstructured":"Akram Q, Roberts M, Oddis C, Herrick A, Chinoy H (2016) Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease. Reumatologia 54:35\u201337. https:\/\/doi.org\/10.5114\/reum.2016.58760","journal-title":"Reumatologia"},{"key":"4515_CR84","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/03009742.2016.1231341","volume":"46","author":"S Ebata","year":"2017","unstructured":"Ebata S, Yoshizaki A, Fukasawa T et al (2017) Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease. Scand J Rheumatol 46:247\u2013252. https:\/\/doi.org\/10.1080\/03009742.2016.1231341","journal-title":"Scand J Rheumatol"},{"key":"4515_CR85","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00296-017-3654-0","volume":"37","author":"F Dall\u2019Ara","year":"2017","unstructured":"Dall\u2019Ara F, Lazzaroni MG, Antonioli CM, Air\u00f2 P (2017) Systemic sclerosis with anti-RNA polymerase III positivity following silicone breast implant rupture: possible role of B-cell depletion and implant removal in the treatment. Rheumatol Int 37:847\u2013851. https:\/\/doi.org\/10.1007\/s00296-017-3654-0","journal-title":"Rheumatol Int"},{"key":"4515_CR86","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/1346-8138.14189","volume":"45","author":"H Numajiri","year":"2018","unstructured":"Numajiri H, Yoshizaki A, Ebata S et al (2018) Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide. J Dermatol 45:e140\u2013e141. https:\/\/doi.org\/10.1111\/1346-8138.14189","journal-title":"J Dermatol"},{"key":"4515_CR87","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00296-019-04357-x","volume":"39","author":"K Melissaropoulos","year":"2019","unstructured":"Melissaropoulos K, Kraniotis P, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D (2019) Targeting very early systemic sclerosis: a case-based review. Rheumatol Int 39:1961\u20131970. https:\/\/doi.org\/10.1007\/s00296-019-04357-x","journal-title":"Rheumatol Int"},{"key":"4515_CR88","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","volume":"74","author":"S Jordan","year":"2015","unstructured":"Jordan S, Distler JHW, Maurer B et al (2015) Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74:1188\u20131194. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204522","journal-title":"Ann Rheum Dis"},{"key":"4515_CR89","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G et al (2017) A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 46:625\u2013631. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.003","journal-title":"Semin Arthritis Rheum"},{"key":"4515_CR90","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","volume":"17","author":"M Thiebaut","year":"2018","unstructured":"Thiebaut M, Launay D, Rivi\u00e8re S et al (2018) Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev 17:582\u2013587. https:\/\/doi.org\/10.1016\/j.autrev.2017.12.010","journal-title":"Autoimmun Rev"},{"key":"4515_CR91","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","volume":"78","author":"M Elhai","year":"2019","unstructured":"Elhai M, Boubaya M, Distler O et al (2019) Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 78:979\u2013987. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214816","journal-title":"Ann Rheum Dis"},{"key":"4515_CR92","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.autrev.2018.10.006","volume":"18","author":"J Narv\u00e1ez","year":"2019","unstructured":"Narv\u00e1ez J, Pirola JP, Lluch J, Juarez P, Nolla JM, Valenzuela A (2019) Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: a case series and systematic review of the literature. Autoimmun Rev 18:262\u2013269. https:\/\/doi.org\/10.1016\/j.autrev.2018.10.006","journal-title":"Autoimmun Rev"},{"key":"4515_CR93","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis SNC, Tsamandas AC et al (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49:271\u2013280. https:\/\/doi.org\/10.1093\/rheumatology\/kep093","journal-title":"Rheumatology (Oxford)"},{"key":"4515_CR94","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","volume":"57","author":"G Sircar","year":"2018","unstructured":"Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P (2018) Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford) 57:2106\u20132113. https:\/\/doi.org\/10.1093\/rheumatology\/key213","journal-title":"Rheumatology (Oxford)"},{"key":"4515_CR95","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1186\/s13104-018-3994-1","volume":"11","author":"VS Vilela","year":"2018","unstructured":"Vilela VS, Da Silva BRA, Da Costa CH, Lopes AJ, Levy RA, Rufino R (2018) Effects of treatment with rituximab on microcirculation in patients with long-term systemic sclerosis. BMC Res Notes 11:874.\u00a0https:\/\/doi.org\/10.1186\/s13104-018-3994-1","journal-title":"BMC Res Notes"},{"key":"4515_CR96","doi-asserted-by":"publisher","first-page":"R145","DOI":"10.1186\/ar3879","volume":"14","author":"D Daoussis","year":"2012","unstructured":"Daoussis D, Tsamandas AC, Liossis SNC et al (2012) B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther 14:R145.\u00a0https:\/\/doi.org\/10.1186\/ar3879","journal-title":"Arthritis Res Ther"},{"key":"4515_CR97","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13075-016-1017-y","volume":"18","author":"D Daoussis","year":"2016","unstructured":"Daoussis D, Tsamandas A, Antonopoulos I et al (2016) B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Res Ther 18:118\u00a0https:\/\/doi.org\/10.1186\/s13075-016-1017-y","journal-title":"Arthritis Res Ther"},{"key":"4515_CR98","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00296-019-04350-4","volume":"39","author":"I Antonopoulos","year":"2019","unstructured":"Antonopoulos I, Daoussis D, Lalioti ME et al (2019) B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis. Rheumatol Int 39:1889\u20131898. https:\/\/doi.org\/10.1007\/s00296-019-04350-4","journal-title":"Rheumatol Int"},{"key":"4515_CR99","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","volume":"18","author":"E Schiopu","year":"2016","unstructured":"Schiopu E, Chatterjee S, Hsu V et al (2016) Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther 18:131. https:\/\/doi.org\/10.1186\/s13075-016-1021-2","journal-title":"Arthritis Res Ther"},{"key":"4515_CR100","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1002\/art.40656","volume":"70","author":"K Streicher","year":"2018","unstructured":"Streicher K, Sridhar S, Kuziora M et al (2018) Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (MEDI-551) and correlates with disease activity in systemic lupus erythematosus and chronic obstructive pulmonary disease. Arthritis Rheumatol 70:2087\u20132095. https:\/\/doi.org\/10.1002\/art.40656","journal-title":"Arthritis Rheumatol"},{"key":"4515_CR101","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1165\/rcmb.2007-0320OC","volume":"39","author":"S Fineschi","year":"2008","unstructured":"Fineschi S, Bongiovanni M, Donati Y et al (2008) In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis. Am J Respir Cell Mol Biol 39:458\u2013465. https:\/\/doi.org\/10.1165\/rcmb.2007-0320OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"4515_CR102","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1186\/ar2991","volume":"12","author":"L Goffin","year":"2010","unstructured":"Goffin L, Seguin-Estevez Q, Alvarez M, Reith W, Chizzolini C (2010) Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts. Arthritis Res Ther 12:R73. https:\/\/doi.org\/10.1186\/ar2991","journal-title":"Arthritis Res Ther"},{"key":"4515_CR103","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon JK, Martyanov V, Franks JM et al (2018) Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol 70:308\u2013316. https:\/\/doi.org\/10.1002\/art.40358","journal-title":"Arthritis Rheumatol"},{"key":"4515_CR104","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/ard.2006.060772","volume":"66","author":"F Lavie","year":"2007","unstructured":"Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg J-E, Mariette X (2007) Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 66:700\u2013703. https:\/\/doi.org\/10.1136\/ard.2006.060772","journal-title":"Ann Rheum Dis"},{"key":"4515_CR105","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/art.22289","volume":"56","author":"CP Denton","year":"2007","unstructured":"Denton CP, Merkel PA, Furst DE et al (2007) Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192. Arthritis Rheum 56:323\u2013333. https:\/\/doi.org\/10.1002\/art.22289","journal-title":"Arthritis Rheum"},{"key":"4515_CR106","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1172\/JCI77958","volume":"125","author":"LM Rice","year":"2015","unstructured":"Rice LM, Padilla CM, McLaughlin SR et al (2015) Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 125:2795\u20132807. https:\/\/doi.org\/10.1172\/JCI77958","journal-title":"J Clin Invest"},{"key":"4515_CR107","first-page":"1103","volume":"23","author":"JD Isaacs","year":"1996","unstructured":"Isaacs JD, Hazleman BL, Chakravarty K, Grant JW, Hale G, Waldmann H (1996) Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. J Rheumatol 23:1103\u20131106","journal-title":"J Rheumatol"},{"key":"4515_CR108","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/bmt.2010.209","volume":"46","author":"J Styczynski","year":"2011","unstructured":"Styczynski J, Tallamy B, Waxman I et al (2011) A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 46:790\u2013799. https:\/\/doi.org\/10.1038\/bmt.2010.209","journal-title":"Bone Marrow Transplant"},{"key":"4515_CR109","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.rdc.2019.04.003","volume":"45","author":"J Spierings","year":"2019","unstructured":"Spierings J, van Laar JM (2019) Is there a place for hematopoietic stem cell transplantation in rheumatology? Rheum Dis Clin North Am 45:399\u2013416. https:\/\/doi.org\/10.1016\/j.rdc.2019.04.003","journal-title":"Rheum Dis Clin North Am"},{"key":"4515_CR110","unstructured":"Mantero JC, Kishore N, Ziemek J, et al. (2018) Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I\/II biomarker trial. Clin Exp Rheumatol 36 Suppl 113:146\u2013149."},{"key":"4515_CR111","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1002\/art.27647","volume":"62","author":"C Beyer","year":"2010","unstructured":"Beyer C, Schett G, Distler O, Distler JHW (2010) Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 62:2831\u20132844. https:\/\/doi.org\/10.1002\/art.27647","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04515-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-020-04515-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04515-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:14:31Z","timestamp":1611015271000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-020-04515-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":111,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4515"],"URL":"https:\/\/doi.org\/10.1007\/s00296-020-04515-6","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,20]]},"assertion":[{"value":"13 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Durga Prasanna Misra declares that he has no conflict of interest, including no relationship with pharmaceutical companies. Sakir Ahmed declares that he has no conflict of interest, including no relationship with pharmaceutical companies. Vikas Agarwal declares that he has no conflict of interest, including no relationship with pharmaceutical companies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}